(Press-News.org) (ORLANDO, Dec. 6, 2025) Within a year of initiation, a multidisciplinary project to improve screening and treatment for iron deficiency in pregnancy resulted in a sixfold rise in screening rates for iron deficiency in pregnant patients, a 20-fold rise in the number of intravenous (IV) iron infusions, and a significant improvement in median hemoglobin levels.
“Screening rates went from 10% to over 60% within a year,” said lead author Richard Godby, MD, a hematologist at the Mayo Clinic in Rochester, Minnesota. “Two-thirds of pregnant patients screened were found to be iron deficient, indicating that this is a very common, but readily fixable problem.”
Women of child-bearing age are at high risk for iron deficiency. Menstruation and low intake of iron-rich foods are some of the most common causes of iron deficiency among women in this age group, Dr. Godby said. In addition, some commonly used medications, such as proton pump inhibitors, can inhibit the body’s ability to absorb iron.
The body needs more iron during pregnancy. Iron deficiency and anemia during pregnancy have been associated with adverse outcomes such as fetal growth restriction, premature birth, low birth weight, and compromised development of the fetus’s brain and nervous system.
Iron deficiency can be diagnosed with a blood test for ferritin, a protein that enables the body to store iron. However, guidelines from the American College of Obstetrics and Gynecology – the professional society that represents most U.S. doctors in this specialty – currently recommend iron deficiency screening only for pregnant women with anemia, which they define as a hemoglobin level below 11 g/dL in the first or third trimester.
Dr. Godby and his colleagues worked with a multidisciplinary team at the Mayo Clinic to develop and implement a quality improvement project aimed at standardizing the screening and treatment of iron deficiency in pregnancy. They added ferritin testing to the list of recommended lab tests that patients typically undergo at eight to 12 weeks of pregnancy and again at 24 to 28 weeks. If patients had low ferritin levels at eight to 12 weeks, their teams offered to prescribe oral iron supplements. If patients’ ferritin was low at 24 to 28 weeks, the teams offered them an IV infusion of iron dextran.
To measure the project’s results, the research team compared changes after project implementation between the two cohorts of patients – one treated before implementation (2,097 pregnancies; the Before cohort) and one treated a year later, after implementation (2,429 pregnancies; the After cohort).
Results showed that, in the Before cohort, just 10% of patients underwent ferritin testing, compared with 63% in the After cohort. Among those tested, 66% in the Before cohort and 69% in the After cohort were iron deficient. Just 0.9% of patients in the Before cohort received IV iron dextran infusions, compared with 21% in the After cohort.
Among patients who received IV iron infusions, the median hemoglobin level improved from 10.7 to 11.8 g/dL. Patients whose hemoglobin level was 12 g/dL at study entry (above the cutoff of 11 g/dL to be considered anemic according to current guidelines from the American College of Obstetricians and Gynecologists) saw an increase to 12.8 g/dL. “These findings suggest reassessing the threshold for diagnosing anemia and screening for iron deficiency in pregnancy,” Dr. Godby said.
Before the project, 3.1% of pregnancies required a blood transfusion during hospitalization for delivery, compared with 2.7% after the project’s implementation. Most patients who needed blood transfusions had not been tested for iron deficiency. While this difference was not statistically significant, Dr. Godby said, it suggests that a reduction in the need for post-partum blood transfusions could be an additional benefit of treating iron deficiency during pregnancy.
Dr. Godby noted that nearly all of the patients in both the Before and After cohorts took prenatal vitamins, which are recommended during pregnancy and supposed to contain iron. However, these supplements were usually purchased over the counter rather than prescribed by the health care team. Over-the-counter dietary supplements are not regulated to ensure they contain the ingredients and amounts of ingredients claimed by the manufacturers, he said.
As a next step, the team hopes to analyze whether treating iron deficiency in pregnancy improves patients’ quality of life by enabling them to feel better, experience less post-partum depression, return to work sooner, and more.
Richard Godby, MD, of the Mayo Clinic, will present this study on Sunday, December 7, 2025, at 12:00 noon Eastern time in W304A-D of the Orange County Convention Center.
###
The American Society of Hematology (ASH) (hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. Join the #Fight4Hematology by visiting hematology.org/fight4hematology.
The Blood journals (https://ashpublications.org/journals) are the premier source for basic, translational, and clinical hematologic research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide.
END
Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy
2025-12-06
ELSE PRESS RELEASES FROM THIS DATE:
IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection
2025-12-06
(ORLANDO, Dec. 6, 2025) Treatment with intravenous (IV) iron significantly improved survival and increased hemoglobin levels in patients with iron-deficiency anemia who were hospitalized for an acute bacterial infection, according to an analysis of data from more than 85,000 patients.
“Our data show that it is safe to give IV iron to patients who have both iron-deficiency anemia and an acute bacterial infection, and that, compared with untreated patients, those treated with IV iron have better overall survival and higher hemoglobin levels,” said lead author Haris Sohail, MD, a fellow in hematology-oncology at Charleston Area Medical ...
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
2025-12-06
(ORLANDO, Dec. 6, 2025) Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more than 20% more likely to die of any cause, according to an analysis of data conducted over a 34-year period and supported by the National Cancer Institute (NCI) is a component of the U.S. National Institutes of Health. Among patients with a mutation in their cancer cells that is generally associated with more favorable outcomes from AML treatment, survival for Black patients was ...
Emergency departments fall short on delivering timely treatment for sickle cell pain
2025-12-06
(ORLANDO, Dec. 6, 2025) A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications within the first hour as recommended by the American Society of Hematology (ASH) and National Heart, Lung, and Blood Institute (NHLBI).
Based on data from several hundred medical centers across the United States, the research represents the first large, national study to assess guideline adherence across diverse EDs. It shows substantially ...
Study shows no clear evidence of harm from hydroxyurea use during pregnancy
2025-12-06
(ORLANDO, Dec. 6, 2025) Taking the sickle cell drug hydroxyurea during or shortly before pregnancy does not appear to cause specific issues in newborns, according to the first prospective study of pregnancies involving hydroxyurea exposure.
Since there may yet be undocumented effects, the authors still recommend discontinuing the drug before pregnancy, if possible. However, the findings offer reassurance that hydroxyurea exposure may not cause harm when unplanned pregnancies occur or when the drug is the only or best option ...
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
2025-12-06
(ORLANDO, Dec. 6, 2025) Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after their procedure, according to a new study. The study included over 1,000 patients, representing the largest and most comprehensive analysis of long-term transplant outcomes to date in people living with sickle cell disease.
“A majority of patients in this cohort are alive; the transplant worked so they no longer show symptoms of their sickle cell disease, and most have had no late effects post-transplant,” said lead study author Elizabeth Stenger, ...
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
2025-12-06
(ORLANDO, Dec. 6, 2025) The first study assessing the real-world commercial roll-out of gene therapies for sickle cell disease and beta thalassemia offers lessons learned to inform best practices as manufacturers and medical centers prepare to meet growing demand for gene therapies in the coming years.
“Gene therapy requires system-level coordination and close collaboration across patients, treatment centers, payers, and manufacturers,” said study author Joanne Lager, MD, chief medical officer at Genetix Biotherapeutics Inc. “The demand for these one-time durable gene ...
Early results suggest exa-cel gene therapy works well in children
2025-12-06
(ORLANDO, Dec. 6, 2025) Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger than 12. Researchers say the therapy’s potential to offer a cure at an early age – before organ damage accumulates – could make exa-cel even more beneficial in children than adults.
“All younger patients with sufficient follow-up met the primary endpoint of being transfusion independent in those with beta thalassemia and free of vaso-occlusive crises for those with sickle cell disease,” said ...
NTIDE: Disability employment holds steady after data hiatus
2025-12-05
East Hanover, NJ – December 5, 2025 – The December 2025 National Trends in Disability Employment (nTIDE) report shows that employment outcomes for working-aged people with disabilities remain near historic highs, despite broader economic uncertainty. nTIDE reporting was on hiatus while the federal government shutdown delayed the release of employment data, which only recently became available.
Although employment and labor force participation edged down slightly in September, both measures continue to outperform year-to-year trends for workers without disabilities. Overall, the findings point to sustained labor market engagement among people with disabilities, ...
Social lives of viruses affect antiviral resistance
2025-12-05
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing.
Ph.D. student Alexander J. Robertson in the Molecular & Cellular Biology program at the University of Washington is among those scientists.
“I study the evolution of antimicrobial resistance through mechanisms which require interaction between microbes,” he explained.
This week he is the lead author of a paper in Nature Ecology & Evolution on that topic.
Polioviruses ...
Dose of psilocybin, dash of rabies point to treatment for depression
2025-12-05
ITHACA, N.Y. – An international collaboration led by Cornell University researchers used a combination of psilocybin and the rabies virus to map how – and where – the psychedelic compound rewires the connections in the brain.
Specifically, they showed psilocybin weakens the cortico-cortical feedback loops that can lock people into negative thinking. Psilocybin also strengthens pathways to subcortical regions that turn sensory perceptions into action, essentially enhancing sensory-motor responses.
The ...